All News
Filter News
Found 85 articles
-
ZyVersa Therapeutics Appoints Three New Board Members
1/5/2023
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa") announced today the appointments of three new independent board members, bringing the total board membership to seven.
-
Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both
12/12/2022
Blue Water Vaccines Inc. today announced its first analyst coverage since going public in February 2022 with the initial recommendations as “buy” from both Maxim Group LLC (“Maxim”) and H.C. Wainwright & Co. (“H.C. Wainwright”) at price targets of $4 and $7, respectively.
-
Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate
12/6/2022
Blue Water Vaccines Inc. today announced the Company will host an online Key Opinion Leader (“KOL”) event on Wednesday, December 7, 2022 from 12 p.m. – 2 p.m. EST.
-
Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine
12/1/2022
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced that Ali Fattom, Ph.D., will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego, California on Thursday, December 1, 2022.
-
Influenza Vaccine Market Size, Growth, Trends | Report 2022-2030
11/28/2022
The global influenza vaccine market was estimated at USD 7.02 billion in 2021 and it is expected to surpass around USD 15.13 billion by 2030, poised to grow at a CAGR of 8.91% from 2022 to 2030.
-
Blue Water Vaccines Announces Exclusive, Global License Agreement for Chlamydia Vaccine Candidate Development from The University of Texas Health San Antonio
11/21/2022
Blue Water Vaccines Inc. a biopharmaceutical company developing transformational vaccines to address significant global health challenges, announced the signing of an exclusive, global license agreement for the development of a live attenuated, oral Chlamydia vaccine candidate from The University of Texas Health San Antonio.
-
RSV, influenza, COVID-19 and monkeypox have dominated vaccine discussions this year, but vaccines are also being developed for a host of other infectious diseases.
-
Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program
11/10/2022
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced its financial results for the third quarter ended September 30, 2022 and provided an update on recent business developments and progress.
-
In the near future, painful jabs and muscle soreness that persists for days could be replaced by new immunization approaches including intradermal delivery, edible and intranasal vaccines.
-
Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia at the World Vaccine Congress in Barcelona
10/11/2022
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”) today announced plans to investigate the ability of BWV-201, a Streptococcus pneumoniae vaccine candidate for acute otitis media (“AOM”) prevention, to also protect against non-invasive pneumococcal pneumonia at the World Vaccine Congress in Barcelona.
-
Blue Water Vaccines to Present at World Vaccine Congress Europe 2022
9/21/2022
Blue Water Vaccines Inc. today announced that the Company will host a roundtable discussion and present at the World Vaccine Congress Europe 2022 in Barcelona, Spain.
-
Blue Water Vaccines to Present In Person and via Webcast at H.C. Wainwright’s 24th Annual Global Investment Conference in New York, NY
9/8/2022
Blue Water Vaccines Inc. a biopharmaceutical company developing transformational vaccines to address significant global health challenges, announced an update to its presentation at the H.C. Wainwright 24th Annual Global Investment Conference.
-
Blue Water Vaccines to Present at H.C. Wainwright’s 24th Annual Global Investment Conference in New York, NY
8/31/2022
Blue Water Vaccines Inc. announced that Joseph Hernandez, Chairman and Chief Executive Officer, will present at H.C. Wainwright’s 24th Annual Global Investment Conference, held from September 12-14, 2022, in New York, NY.
-
Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom
8/24/2022
Blue Water Vaccines Inc. today announced that scientists from its research partner, The University of Oxford, will present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom on Monday, September 5th , 2022.
-
Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors
8/22/2022
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the appointment of Simon Tarsh, seasoned financial consultant with experience in the life science industry, to its board of directors at BWV’s annual meeting.
-
Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate
8/17/2022
Blue Water Vaccines Inc. today announced that the Company plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion virus-like particle (VLP) platform.
-
After more than two decades of attempts to develop a universal influenza vaccine, the global COVID-19 pandemic intensified the need for a broader vaccine for both illnesses.
-
Blue Water Vaccines Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8/15/2022
Blue Water Vaccines Inc. announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent business developments and progress.
-
Blue Water Vaccines Announces $10 Million Private Placement Priced At-the-Market under Nasdaq Rules
8/9/2022
Blue Water Vaccines Inc. today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase of 3,683,280 shares of common stock (or common stock equivalents in lieu thereof) in a private placement priced at-the-market under Nasdaq rules.
-
Postpartum Depression Market Boosting the Growth Worldwide: Dynamics and Trends, Efficiencies Forecast 2030
7/25/2022
Forecast to 2030,’ thoroughly examines the Postpartum Depression industry to provide essential data & information for the targeted readers.